DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for external ear disease — screening already-approved drugs against its 33-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleExternal ear disease maps to a 33-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for external ear disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
VRK serine/threonine kinase 2 (VRK2) — VRK2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet sindrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2V62 · 1.7 Å · ligand SUCCINIC ACID (SIN). Experimental structure, not a prediction.
What the evidence adds up to
A 2021 review reports that approximately ten percent of humans may face otitis externa during their lifetime, and that most of the time the infection is mixed. The same review states that medical intervention of the ear can prove painful for most cases, and that post-surgery analgesics must be utilised for a time period the treating physician prescribes. A 2018 paper reviews clinical studies on the effectiveness of a complex drug with antibacterial, antiinflammatory and antiedematous action based on neomycin, polymyxin B and dexamethasone, but provides no concrete survival or response rate numbers from those studies.
A 1957 paper argues that an individual case of external otitis should not be considered idiopathic until a definitive diagnosis cannot be made, and that a dermatitis of the external auditory canal can represent the first manifestation of a systemic disease. Therapeutic success, according to that paper, often depends on the physician's ability to interpret anamnestic, clinical, and laboratory findings. A 2013 article notes that the classification of otitis externa has been modified to include a combination of causes and factors, covering primary and secondary causes, predisposing and perpetuating factors.
A 1993 report describes two cases and reviews four others from the literature where cannabis was lodged in the external ear, noting that ENT surgeons may be asked to remove it and that anyone working with people who abuse drugs should be aware cannabis can be concealed there. The 2021 review concludes that the efficacy of operative modalities for extremes of otitis externa will rely on complete patient examination, history and lab results, and that it is never easy to avoid otitis externa but one can make an effort to decrease the risk.
What is still missing are controlled trials that report concrete response rates or survival data for any specific drug regimen in external ear disease, along with standardised patient stratification by aetiology and severity, and funding for such trials rather than reliance on narrative reviews and case series.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAMA · 1957 · 6 citations
A PRACTICAL APPROACH TO EXTERNAL OTITIS
Abstract• An individual case of external otitis should not be considered to be idiopathic until it has been shown that a definitive diagnosis cannot be made. Establishment of an etiological diagnosis can be facilitated by clues derived from a careful history (e.g., dermatitis of other areas) and extensive clinical and laboratory examination (e.g., biopsy, if indicated). A dermatitis of the external auditory canal can represent the first manifestation of a systemic disease. Therapeutic success often depends on the physician's ability to interpret the anamnestic, clinical, and laboratory findings.
AbstractThis article discusses otitis externa, inflammation of the external ear canal, the classification of which has been modified to include a combination of causes and factors. Primary and secondary causes, predisposing and perpetuating factors, clinical features, diagnosis, treatment and prognosis are considered.
The Journal of Laryngology & Otology · 1993 · 3 citations
Cannabis in the external ear
AbstractENT surgeons may well be asked to remove cannabis from the external ear where it has been lodged for various reasons. We report two cases and review four other cases we found in the literature to illustrate some of the difficulties. It is important that anyone working with people who abuse drugs are aware that cannabis can be concealed in the external ear.
Journal of Pharmaceutical Research International · 2021 · 1 citations · open access
A Review on Otitis externa: An Approach to a Etiopathogenesis, Epidemiology, Clinical Features and Management Protocol
AbstractIntroduction: The external ear is the part of our ears which is seen from outside. It is made up of the auricles (pinna) and external auditory canal; and, includes the outer wall of the middle ear, i.e. the eardrum. Otitis externa is a regular presentation when on call for ENT or at the emergency ENT health clinic or centre. Infective and reaction groups of otitis externa are classified. Methodology: The articles reviewed in this narrative review article have been traced from a variety of links and sources over the internet like PubMed, NCBI, ScienceDirect, NHSINFORM, Uptodate, WebmedCentral, American family physician, ClevelandClinic, StatPearls, and many more. References from high yielding sources were taken and the articles were properly assessed. Results: Paying attention to the scientific elements while performing an operative procedure can give a physician extended results. Which operative modality to be chosen depends on the patient. The patient’s choices are also important in the decision making of the operation. Discussion: External otitis is possibly spotted in almost every peer category. Approximately ten percent (10%) of humans may face this condition during their lifetime. Most of the time, the infection is mixed. Medical intervention of the ear can prove painful for most cases, therefore, post-surgery analgesics must be utilized for a time period which the treating physician prescribes. The aim of curing the patient is to free him/her from the symptoms and getting rid-off any pathogen causing a specific infection. Conclusion: The efficacy of operative modalities of extremes of otitis externa will rely on complete patient examination, history and lab results. Selection of the correct intervention, proper knowlege of the regional anatomy, paying attention to scientific elements and good post-operative care is necessary. It is never easy to avoid otitis externa, but we can make an effort to decrease the risk of developing this problem.
Meditsinskiy sovet = Medical Council · 2018 · 1 citations · open access
The principles of the treatment of patients with external ear inflammatory diseases
AbstractThe article reflects the issues of the management of patients with external ear inflammatory diseases. Authors describe the pathogenetic and etiological factors of this pathology development. In the article the principles of conservative treatment and the possibility of using measures that prevent relapses are described, depending on the severity and nature of the pathological process. The paper consists a brief review of clinical studies on the effectiveness of a complex drug with antibacterial, antiinflammatory and antiedematous action based on neomycin, polymyxin B and dexamethasone is reviewed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
